A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis – the HUMOR trial

Aitken, Dawn; Laslett, Laura L; Pan, Feng; Haugen, Ida K.; Otáhal, Petr; Bellamy, Nicholas; Bird, Paul; Jones, Graeme

doi:10.1016/j.joca.2018.02.899

Cited by 117 publications

(85 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, studies of adalimumab have not shown it to be effective compared to placebo in reducing symptoms of hand OA [83,84]. More recently, the HUMOR trial compared subcutaneous adalimumab 40 mg on alternative weeks versus placebo over 12 weeks in a crossover-design study of 43 patients with erosive hand OA and synovitis seen on magnetic resonance imaging (MRI) [85]. There was an 8-week washout period before treatment groups crossed over.…”

Section: Tumour Necrosis Factor Inhibitorsmentioning

confidence: 99%

Prospects for Therapies in Osteoarthritis

Ghouri

Conaghan

2020

Calcif Tissue Int

View full text Add to dashboard Cite

Osteoarthritis (OA) is a chronic, debilitating disease affecting millions of people worldwide. Management of OA involves pharmacological and non-pharmacological approaches. Conventional pharmacological treatments have limited efficacy and are associated with a number of side-effects, restricting the number of patients who can use them. New pharmacological therapies for managing OA are required and a number have been developed targeting different tissues in OA: bone and cartilage, synovium and nerves. However, there has been overall limited success. Disease-modifying osteoarthritis drugs (DMOADs) are a putative class of therapies aimed at improving OA structural pathologies and consequent symptoms. Recent DMOAD studies have demonstrated some promising therapies but also provided new considerations for future trials.

show abstract

Section: Tumour Necrosis Factor Inhibitorsmentioning

confidence: 99%

Prospects for Therapies in Osteoarthritis

Ghouri

Conaghan

2020

Calcif Tissue Int

View full text Add to dashboard Cite

show abstract

“…102 Currently, no DMOADs have been licensed for use in the treatment of OA, but several putative DMOADs are in phase II development. In particular, monoclonal antibodies (mAbs) and inhibitors directed against OA-related cytokines, such as tumor necrosis factor α (TNF-α), [103][104][105][106] nerve growth factor, [107][108][109] or interleukin molecules like IL-1α/β, [110][111][112] are under investigation, due to their regular use as biological disease-modifying antirheumatic drugs (bDMARDs) for the management of rheumatoid arthritis inflammation. 113 In a report comparing safety outcomes of bDMARDs in rheumatoid arthritis in 42 observational studies, a general safety profile of bDMARDs emerged with very sporadic cases of cardiovascular and infection incidence.…”

Section: Monoclonalmentioning

confidence: 99%

Management of Osteoarthritis During the COVID‐19 Pandemic

Ragni

Mangiavini

Viganò

et al. 2020

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

The pandemic spread of the new coronavirus disease 2019 (COVID‐19) infection in China first, and all over the world at present, has become a global health emergency due to the rapidly increasing number of affected patients. Currently, a clear relationship between COVID‐19 infection incidence and/or complications due to chronic or occasional treatments for other pathologies is still not clear, albeit the COVID‐19 pandemic may condition the treatment strategy of complex disorders, such as osteoarthritis (OA). Importantly, OA is the most common age‐related joint disease, affecting more than 80% of people older than the age of 55, an age burden also shared with the highest severity in COVID‐19 patients. OA patients often show a large array of concomitant pathologies, such as diabetes, inflammation, and cardiovascular diseases that are again shared with COVID‐19 patients and may therefore increase complications. Moreover, different OA treatments, such as NSAIDs, paracetamol, corticosteroids, opioids, or other molecules have a wide array of iatrogenic effects, potentially increasing COVID‐19 secondary infection incidence or complications. In this review we critically analyze the evidence on either negative or positive effects of drugs commonly used to manage OA in this particular scenario. This would provide orthopedic surgeons in particular, and physicians, pharmacologists, and clinicians in general, a comprehensive description about the safety of the current pharmacological approaches and a decision‐making tool to treat their OA patients as the coronavirus pandemic continues.

show abstract

“…Another example is the TNF-α inhibitor etanercept (Enbrel ® ) which was the first biopharmaceutical on the market approved by U.S. F.D.A to treats chronic autoimmune and inflammatory diseases such as rheumatoid arthritis, juvenile rheumatoid arthritis and psoriatic arthritis (Rider et al, 2016). A further example is, Adalimumab (Humira ® ), a fully human monoclonal antibody against TNF-α, that can relieve symptoms of autoimmune diseases, reduce inflammation and inhibit chronic pain (Aitken et al, 2018). The TNF-α inhibitors, certolizumab and golimumab, were also approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and Crohn's disease unresponsive to regular medications (Rider et al, 2016).…”

Section: Cytokines As Targets For the Development Of Drugsmentioning

confidence: 99%

Monoterpenes modulating cytokines - A review

Quintans

Saravanan

Heimfarth

et al. 2019

Food and Chemical Toxicology

View full text Add to dashboard Cite

Inflammatory response can be driven by cytokine production and is a pivotal target in the management of inflammatory diseases. Monoterpenes have shown that promising profile as agents which reduce the inflammatory process and also modulate the key chemical mediators of inflammation, such as pro and anti-inflammatory cytokines. The main interest focused on monoterpenes were to develop the analgesic and anti-inflammatory drugs. In this review, we summarized current knowledge on monoterpenes that produce anti-inflammatory effects by modulating the release of cytokines, as well as suggesting that which monoterpenoid molecules may be most effective in the treatment of inflammatory disease. Several different inflammatory markers were evaluated as a target of monoterpenes. The proinflammatory and antiinflammatory cytokines were found TNF-α, IL-1β, IL-2, IL-5, IL-4, IL-6, IL-8, IL-10, IL-12 IL-13, IL-17A, IFNγ, TGF-β1 and IFN-γ. Our review found evidence that NF-κB and MAPK signaling are important pathways for the anti-inflammatory action of monoterpenes. We found 24 monoterpenes that modulate the production of cytokines, which appears to be the major pharmacological mechanism these compounds possess in relation to the attenuation of inflammatory response. Despite the compelling evidence supporting the anti-inflammatory effect of monoterpenes, further studies are necessary to fully explore their potential as anti-inflammatory compounds.

show abstract

A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis – the HUMOR trial

Abstract: ACTRN12612000791831.

Cited by 117 publications

References 24 publications

Prospects for Therapies in Osteoarthritis

Prospects for Therapies in Osteoarthritis

Management of Osteoarthritis During the COVID‐19 Pandemic

Monoterpenes modulating cytokines - A review

Contact Info

Product

Resources

About